Premium
Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders
Author(s) -
FREWIN REBECCA,
TURNER DEBORAH,
TIGHE MARY,
DAVIES SIMON,
RULE SIMON,
JOHNSON STEPHEN
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01212.x
Subject(s) - fludarabine , medicine , cyclophosphamide , nausea , vomiting , gastroenterology , chlorambucil , salvage therapy , purine analogue , refractory (planetary science) , chronic lymphocytic leukemia , lymphoma , chemotherapy , lymphoproliferative disorders , surgery , oncology , leukemia , purine , biochemistry , chemistry , physics , astrobiology , enzyme
Seventeen patients (aged 50–85 years) with relapsed or refractory non‐Hodgkin's lymphoma (NHL, 10 patients) or chronic lymphocytic leukaemia (CLL, seven patients) were treated with a combination of fludarabine 25 mg/m 2 /d and cyclophosphamide 250 mg/m 2 /d for 3 d repeated every 4 weeks. 12 patients had previously received purine analogue therapy of which four had progressive disease during treatment. The overall response rate of patients with CLL was 71% (28% CR, 43% PR) and for NHL was 50% (0% CR, 50% PR). Toxicity consisted of nausea and vomiting which was maximal in the 3 d after therapy, infections and haematological suppression which was prolonged in some patients. This combination, which is based on a rational prediction of synergistic activity, is highly effective but associated with significant problems with tolerance.